Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/30/2025
Locations: Clinical Site, Farmington, Connecticut
Conditions: Major Depressive Disorder
Register for Updates
Ultrasound Effects on Glycemic Control in T2DM
NCT05354947
Recruiting
This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/30/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Type 2 Diabetes
Register for Updates
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
NCT05317455
Recruiting
This is a prospective randomized placebo-controlled double-blind crossover pilot study determining the effect of dichloroacetate on brain function under clamped hypoglycemia in T1DM.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/30/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Diabetes Mellitus, Type 1, Hypoglycemia Unawareness
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/30/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
TrialNet Pathway to Prevention of T1D
NCT00097292
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Blood Pressure Variability and Ischemic Stroke Outcome
NCT05756257
Recruiting
The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: 1. To determine the association of BPV with functional/cognitive outcome after ischemic stroke. 2. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome. 3. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2025
Locations: Yale-New Haven Hospital, New Haven, Connecticut
Conditions: Acute Ischemic Stroke, Blood Pressure Variability
Register for Updates
rTMS as Add on Treatment for Substance Use Disorders
NCT06963476
Recruiting
This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rT... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/27/2025
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Opioid Use, Alcohol Use Disorder
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Yale University School Of Medicine, New Haven, Connecticut
Conditions: Obesity
Register for Updates
Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder
NCT06142955
Recruiting
This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/27/2025
Locations: Yale Psychiatric Hospital, New Haven, Connecticut
Conditions: Autism Spectrum Disorder
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116
Recruiting
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: HER2-positive Metastatic Breast Cancer
Register for Updates